573 results about "Propargyl" patented technology

This invention is directed to compounds of the following formula:wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is 0 or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R1 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted.This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome. Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia.This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

A process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan, a process for isolating from a reaction mixture a crystalline diastereomeric salt of a mono-propargylated aminoindan, and a process for isolating from a reaction mixture a salt of enantiomerically pure N-propargyl-1-aminoindan or a salt of enantiomerically pure 6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan. The corresponding products are also disclosed.

Disclosed is crystalline R(+)-N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure liquid R(+)-N-propargyl-1-aminoindan and a pharmaceutical composition comprising the same, and the process for the manufacture thereof.

Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.

The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.

The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.

The invention relates to 2-[4-(quinoxaline-2-oxygroup) phenoxy] alkylamide shown as a chemical structural formula I or an optical isomer thereof. In the formula, R1 is selected from H, C1-C1alkyl, C3-C4 straight-chain or branch-chain alkyl; R2 is selected from allyl, propargyl, halogenated allyl, halogenated propargyl; and X1-X6 are selected from hydrogen, C1-C2 alkyl, trifluoromethyl, fluorine, chlorine, bromine, nitryl or trifluoromethoxy. The invention further discloses an application of 2-[4-(quinoxaline-2-oxygroup) phenoxy] alkylamide or the optical isomer thereof in preparation of anti-lung adenocarcinoma drugs.

Disclosed is crystalline R(+)-N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure liquid R(+)-N-propargyl-1-aminoindan and a pharmaceutical composition comprising the same, and the process for the manufacture thereof.

The invention provides branched copolymers as precursors for preparing silicon carbide (SiC) ceramics represented by the general formulae:[Si(˜)RC(˜)H]xn[SiR1R2CH2]yn,  Formula Type-Iwherein n is the degree of polymerization, 0.1≦x<0.8, 0.2≦y<0.9 and x+y=1; and R=methyl or H, R1 and R2 are randomly composed of hydrogen (H), allyl, methyl (Me), phenyl (Ph), propargyl or vinyl. Another branched copolymer is represented by the general formula:[Si(˜)RC(˜)H]xn[SiR1R2CH2]yn[SiR3R4CH2]zn  Formula Type-IIwherein n is the degree of polymerization, 0.1≦x<0.8, 0≦y<0.8, 0.2≦z<0.8 and x+y+z=1; and R=methyl or H, R1 and R2 are randomly composed of hydrogen (H), methyl (Me) and phenyl; R3 and R4 are randomly composed of H, allyl, methyl, phenyl (Ph), propargyl, and vinyl. The invention also provides methods for the preparation of such branched copolymers.

The invention discloses a lithium iron phosphate power battery with an improved low temperature charge performance, belongs to the technical field of lithium iron phosphate power batteries, and aims to solve the problem that the negative pole can easily reach a cut-off voltage, and the charge capacity is reduced therefore. The lithium iron phosphate power battery is characterized by comprising a positive plate, a negative plate, and electrolyte. The lithium salt is lithium hexafluorophosphate (11.5-15.0%). The organic solvent is a four component mixed solvent, which is composed of propylene carbonate, methyl carbonate, ethyl carbonate, and diethyl carbonate according to a ratio of 10-40: 1-10: 20-50: 10-30. The additive is one or more of vinylene carbonate, fluoroethylene carbonate, propargyl sulfonate, lithium difluorophosphate, lithium difluoro(oxalato)borate, and lithium tetrafluoro(oxalato)phosphate. The interface impedance of the negative pole can be reduced, the low temperature properties of the lithium iron phosphate power battery are obviously improved, and the low temperature charge performance of the lithium iron phosphate power battery is improved.